Poly (ADP-ribose) polymerase inhibitors are a class of drugs that prevent the DNA repair of cancer cells, thereby destroying them. PARP is an enzyme involved in repairing DNA. Maintenance PARP inhibitor therapy is the second line of treatment for cancer. It is most effective after chemotherapy for ovarian cancer. PARP therapy aims to prolong the time cancer cells need to multiply and recur, offering patients an improved quality of life.
Maintenance PARP inhibitors are very beneficial for ovarian cancer patients. Some benefits include:
Although maintenance PARP therapy is highly effective, it cannot be recommended to all cancer patients.
PARP treatments have been approved for treating the following conditions. They are most effective in patients with BRCA1/2 pathogenic variants or other homologous recombination repair deficiency markers.
Apart from those listed above, PARP inhibitor therapy is also useful in treating advanced ovarian cancer, primary peritoneum and fallopian tube cancers which have responded well to platinum-based therapy, independent of genomic variants. Researchers are now studying about the efficiency of PARP inhibitors to treat the following types of cancers:
Ideal candidates for maintenance PARP therapy are women with ovarian cancer who have had some response to first-line therapy, be it complete or partial. The conditions they must satisfy to receive PARP inhibitor therapy are given below:
Action Cancer Hospital is committed to providing advanced treatment options for ovarian cancer patients. Our oncology department offers the following:
Director
Director